Levetiracetam Tablet, Film Coated
Product Images NDC 68001-405

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68001-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam Tablets Usp 250mg (Image 01)

Label for Levetiracetam Tablets USP, 250 mg strength, film-coated oral tablets. The label indicates a package size of 120 tablets and is labeled for prescription use only. It is produced by BluePoint Laboratories with manufacturing by Aurobindo Pharma Limited. The label includes storage instructions, pharmacist dispensing instructions, and a barcode.*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Bar chart showing the responder rate defined as at least 50% reduction from baseline in Study 1. The chart compares placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day groups. The percentage of patients responding is approximately 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with statistical significance indicated versus placebo.*

FDA Label Image

Levetiracetam Tablets Usp 1000mg (Levetiracetam Fig10)

Levetiracetam Tablets USP 1000 mg film-coated tablets, bottle label for 60 tablets from BluePoint Laboratories. The label includes storage instructions, pharmacist dispensing information, and manufacturer details for Aurobindo Pharma Limited. The label indicates the product is prescription only (Rx only) and features a barcode.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Bar chart showing responder rates with at least 50% reduction from baseline in Study 2: Period A for Levetiracetam tablets. The graph compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Percentages indicate the proportion of patients responding. Statistically significant differences from placebo are marked with asterisks for both Levetiracetam groups.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' shows the percentage of patients responding to treatment. It compares placebo (104 patients) with Levetiracetam 3000 mg/day (180 patients). The responder rate is 14.4% for placebo and 39.4% for Levetiracetam, with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

A bar graph titled 'Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4' showing the percentage of patients responding to treatment. The graph compares Placebo (N=97) with a responder rate of 19.6% and Levetiracetam (N=101) with a responder rate of 44.6%, marked as statistically significant versus placebo.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

A bar graph comparing responder rates for all patients aged 1 month to under 4 years treated with placebo versus levetiracetam in a study. The y-axis shows the percentage of patients achieving at least a 50% reduction from baseline. The levetiracetam group shows a higher responder rate than placebo, with values approximately 43.1% and 19.6%, respectively.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Bar chart depicting responder rate with at least 50% reduction from baseline in PGTC seizure frequency per week in Study 7. The y-axis shows the percentage of patients from 0% to 100%. The chart compares placebo (45.2% responders, N=84) and Levetiracetam (72.2% responders, N=79), with a statistical significance indicator for Levetiracetam versus placebo.*

FDA Label Image

Levetiracetam Tablets Usp 500mg (Levetiracetam Fig8)

Levetiracetam Tablets USP 500 mg film-coated tablets label for oral use by BluePoint Laboratories. The label indicates a package of 120 tablets with directions for pharmacists to dispense with medication guide. It includes storage instructions, manufacturing details by Aurobindo Pharma Limited, and a barcode on the right side.*

FDA Label Image

Levetiracetam Tablets Usp 750mg (Levetiracetam Fig9)

Label for Levetiracetam Tablets USP, 750 mg film-coated tablets by BluePoint Laboratories. The label states Rx only with a count of 120 tablets. It includes storage instructions, usual dosage reference to package insert, and pharmacist dispensing instructions. Manufactured by Aurobindo Pharma Limited, Hyderabad, India.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical structure of levetiracetam showing a pyrrolidone ring attached to an ethyl group and an amide functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.